-+ 0.00%
-+ 0.00%
-+ 0.00%

Seaport Therapeutics Q2 FY26 net loss widens to $62.6 million; R&D expenses rise to $24.62 million

PUBT·08/03/2026 11:00:42
Listen to the news
Seaport Therapeutics Q2 FY26 net loss widens to $62.6 million; R&D expenses rise to $24.62 million
  • Seaport Therapeutics posted a Q2 2026 net loss of USD 62.6 million, widening from USD 15.1 million a year earlier.
  • R&D expense rose to USD 24.62 million from USD 13.41 million, due to higher clinical development spending for GlyphAllo and GlyphAgo.
  • G&A expense climbed to USD 41.19 million from USD 5.06 million, due to one-time, non-cash IPO-related stock compensation and equity grants.
  • Cash, cash equivalents and investments totaled USD 427.3 million at June 30, 2026; Seaport expects this to fund operations into 2029.
  • GlyphAllo Phase 2b BUOY-1 enrollment remains on track with topline data expected in 1H 2027; Phase 1 driving simulation topline data are expected in 2H 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seaport Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608030700BIZWIRE_USPR_____20260803_BW578717) on August 03, 2026, and is solely responsible for the information contained therein.